These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 3742706

  • 21. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
    Crook TR, Souhami RL, McLean AE.
    Cancer Res; 1986 Oct; 46(10):5029-34. PubMed ID: 3463409
    [Abstract] [Full Text] [Related]

  • 22. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY, Teicher BA, Shea TC, Holden SA, Rosbe KW, al-Achi A, Henner WD.
    Cancer Res; 1989 Nov 15; 49(22):6185-92. PubMed ID: 2804968
    [Abstract] [Full Text] [Related]

  • 23. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
    Hemminki K.
    Cancer Res; 1985 Sep 15; 45(9):4237-43. PubMed ID: 4028012
    [Abstract] [Full Text] [Related]

  • 24. Cytochemical characterization of Yoshida sarcoma cells resistant to dibromodulcitol.
    Gáti E, Pokorny E, Somfai-Relle S, Szentirmay Z.
    Int J Tissue React; 1984 Sep 15; 6(1):43-51. PubMed ID: 6715118
    [Abstract] [Full Text] [Related]

  • 25. Some effects of chlorambucil on the uptake and utilization of sulphydryl-containing compounds by tumour cells.
    Harrap KR, Riches PG, Jackson RC, Smith CA.
    Biochem Pharmacol; 1973 Nov 15; 22(22):2881-9. PubMed ID: 4761557
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells.
    Hilton J.
    Biochem Pharmacol; 1984 Jun 15; 33(12):1867-72. PubMed ID: 6732847
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line.
    Andersson BS, Mroue M, Britten RA, Farquhar D, Murray D.
    Acta Oncol; 1995 Jun 15; 34(2):247-51. PubMed ID: 7718264
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein.
    Kawabata TT, White KL.
    Cancer Res; 1988 Jan 01; 48(1):41-5. PubMed ID: 3257162
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE, Powers JF, Grage GM.
    Drug Metab Dispos; 1984 Jan 01; 12(5):553-9. PubMed ID: 6149904
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.